Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action agonists |
Mechanism ACKR3 agonists(atypical chemokine receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Pulmonary Fibrosis | Preclinical | South Korea | 13 Feb 2025 | |
Amyotrophic Lateral Sclerosis | Preclinical | South Korea | 01 Nov 2024 | |
Autoimmune Diseases | Preclinical | South Korea | 01 Nov 2024 | |
Fibrosis | Preclinical | South Korea | 01 Nov 2024 | |
Multiple Sclerosis | Preclinical | South Korea | 01 Nov 2024 | |
Neurodegenerative Diseases | Preclinical | South Korea | 19 Feb 2024 |